Diabetes
Refine Search
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Evotec AG has signed a definitive agreement to acquire fellow Germany-based DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to14 million euros ($17.7 million) in shares plus performance-related deferred payments (earn-out). 19 July 2010
Pharmaceutical
To the delight of GlaxoSmithKline, but no doubt to the surprise - even dismay - of others, US Food and Drug Administration advisors have voted to keep the UK drug giant's type 2 diabetes drug Avandia (rosiglitazone) on the market, despite suggested cardiovascular side effects, albeit with added warnings. The news saw GSK's shares edge 1.1% higher to 11.95 in early trading this morning. 15 July 2010
Pharmaceutical
UK drugs giant GlaxoSmithKline has agreed to pay about $460 million to resolve a majority of law suits alleging the company's type 2 diabetes drug Avandia (rosiglitazone) had caused heart attacks and strokes, reported the Bloomberg news service quoting 'people familiar with the accords,' just as two days of US Food and Drug Administration hearings on the safety of the drug kicked off in Washington DC. The individual settlements are said to range from $46,000 to almost $70,000, depending on the strength of the claims. 14 July 2010
Pharmaceutical
The European Medicines Agency (EMEA) said last Friday that it has started a review of the rosiglitazone-containing anti-diabetes medicines Avandia from UK drugs giant GlaxoSmithKline, as well as the drug sold in combination with metformin (Avandamet) and with glimepiride (Avaglim), to determine whether new data on the risk of cardiovascular problems have an impact on their benefit-risk profile. 12 July 2010
Generics
In what continues to be a busy news week for French drug major Sanofi-Aventis, and another patent victory for Big Pharma, the US Patent and Trade Mark Office has denied a request by Canada-based generic drugmaker Apotex for a second re-examination of the US patent for the firm's blockbuster blood thinner Plavix (clopidogrel), which is co-marketed with Bristol-Myers Squibb, and generated sales of $9.1 billion last year, $5.6 billion in the USA. 1 July 2010
Pharmaceutical
A meta-analysis of previously published studies finds no evidence that statins are associated with a reduced risk of death among individuals at risk for but with no history of cardiovascular disease, according to a report in the June 28 issue of Archives of Internal Medicine, one of the Journal of the American Medical Association (JAMA)/Archives journals. 30 June 2010
Pharmaceutical
US drug major Eli Lilly has signed a development and exclusive license agreement for Marcadia Biotech's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia. The program includes MAR531, a glucagon analog that is in preclinical development at Marcadia, as well as related backup compounds. 29 June 2010
Pharmaceutical
Continuing the string of positive news on diabetes drug developments at the ongoing 70th Scientific Sessions of the American Diabetes Association (ADA) being held in Orlando, Florida, were independent German drug major Boehringer Ingelheim with its linagliptin, and Bristol-Myers Squibb and partner AstraZeneca, which are developing Onglyza (saxagliptin). 29 June 2010
Pharmaceutical
Announcing a second major licensing deal in the same week, French drug major Sanofi-Aventis last Friday entered into a global licensing accord with USA-based and Metabolex for oral agent MBX-2982, a GPR1 19 receptor agonist for the treatment of type 2 diabetes, with the aim of further expanding its already significant footprint in this therapeutic area. 28 June 2010
Pharmaceutical
The 70th American Diabetes Association (ADA) meeting started over the weekend in Orlando, Florida, with a swathe of promising research results for diabetes products, with weight loss a major feature, from leaders in the sector, including from J&J, Novo Nordisk, B-MS/AstraZeneca, Sanofi-Aventis and Roche/Ipsen 28 June 2010
Pharmaceutical
USA-based Metabolex revealed yesterday that it has entered into a global development and license agreement with health care giant Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals subsidiary to further develop and discover compounds for the treatment of type 2 diabetes and other disorders. 23 June 2010
Pharmaceutical
Danish insulin giant Novo Nordisk has decided to re-initiate the global Phase III development program of its diabetes drug of liraglutide for the treatment of obesity. 23 June 2010
Pharmaceutical
Swedish company Diamyd Medical AB has signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, a subsidiary of US health care giant Johnson & Johnson, to develop and commercialize the former's diabetes therapy. The agreement relates to the development and world-wide commercialization of the GAD65 antigen-based therapy Diamyd for the treatment and prevention of type 1 diabetes and associated conditions. 22 June 2010
Pharmaceutical
The diabetes drug candidate taspoglutide, under development by Swiss drug major Roche and France's Ipsen, has run into a difficulty that could delay its approval for up to a year and a half, despite a string of positive, late-stage clinical results over the past several months (The Pharma Letters passim). 21 June 2010
Pharmaceutical
In the space of just 24 hours, USA-based Neurocrine Biosciences has signed a second major licensing deal, this time with independent German drug firm Boehringer Ingelheim for a type 2 diabetes drug candidate that could earn the firm up to $235 million. 18 June 2010
Pharmaceutical
A new consensus statement of experts assembled by the American Diabetes Association and the American Cancer Society reviews emerging evidence that suggests cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. The new report reviews the state of science concerning the association between diabetes and cancer incidence/prognosis; risk factors common to both diseases; possible biologic links between diabetes and cancer risk; and whether diabetes treatments influence the risk of cancer or cancer prognosis. In addition, the report outlines key unanswered questions for future research. 18 June 2010
Pharmaceutical
USA-based Amylin Pharmaceuticals saw its shares fall nearly 4% to $17.10 yesterday morning, after it revealed new clinical data showing that, while its new type 2 diabetes drug candidate Bydureon, an extended-release injectable version of already marketed Byetta (exenatide) beat one comparator drug, it was little better than two others, one of which was the now generic metformin. 16 June 2010
Pharmaceutical
Danish insulin giant Novo Nordisk appears to have backed down in its fight with the Greek government over the draconian drug price cuts - averaging 25% - imposed, which led to the company (as well as fellow Denmark-based LEO Pharma) to say that it would not supply some of its products (the so-called modern insulins or insulin analogues) to the country as it would not only be uneconomic, but would likely lead to parallel trading and calls for reductions in other markets (The Pharma Letter June 1). 15 June 2010
Pharmaceutical
The National Institute of Clinical Excellence (NICE), the rationing body for medical treatment under the UK's National Health Service in England and Wales, yesterday released a revised preliminary recommendation on the use of Danish insulin giant Novo Nordisk's Victoza (liraglutide) for patients with type 2 diabetes, following a second appraisal committee meeting held in April. Final guidance is expected as early as October this year. 15 June 2010
Generics
Israeli generic drugs giant Teva Pharmaceutical Industries Ltd. has exercised its option to invest an additional $11.9 million in diabetes drug developer Andromeda Biotech at a company value of $170 million, report the local news service Globes Online. 15 June 2010
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze